• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013 - Product Image

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013

  • Published: September 2013
  • 73 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AEterna Zentaris Inc.
  • iCo Therapeutics Inc.
  • Merck KGaA
  • MOLOGEN AG
  • Pieris AG
  • MORE

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar). Leishmaniasis (Kala-Azar) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leishmaniasis (Kala-Azar).
- A review of the Leishmaniasis (Kala-Azar) products under development READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Leishmaniasis (Kala-Azar) Overview
Therapeutics Development
An Overview of Pipeline Products for Leishmaniasis (Kala-Azar)
Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies
Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Leishmaniasis (Kala-Azar) Therapeutics - Products under Development by Companies
Leishmaniasis (Kala-Azar) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Leishmaniasis (Kala-Azar) Therapeutics Development
Merck KGaA
iCo Therapeutics Inc.
AEterna Zentaris Inc.
MOLOGEN AG
Advinus Therapeutics Pvt. Ltd.
Pieris AG
Dafra Pharma International Ltd.
aRigen Pharmaceuticals, Inc.
Georgia Tech Research Corporation
Leishmaniasis (Kala-Azar) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PRS-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sitamaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-1331 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleylphosphocholine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEISH-F3 GLA-SE Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-605240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neglected Diseases Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine For Leishmania - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin B NanoDisk - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chalcone Derivatives - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Parasitic Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Cutaneous Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neglected Disease Program 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neglected Disease Program 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bisnaphthalimido Derivatives - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nonpeptide Macrocyclic Histone Deacetylase (HDAC) Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs For Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-010-265 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-010-269 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDRI-99/288 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Compound-2d - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leishmaniasis (Kala-Azar) Therapeutics - Drug Profile Updates
Leishmaniasis (Kala-Azar) Therapeutics - Discontinued Products
Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products
Leishmaniasis (Kala-Azar) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis
Dec 17, 2012: PATH’s Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
Jan 09, 2012: Study Confirms New Strategy In Fight Against Infectious Diseases
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Leishmaniasis (Kala-Azar), H2 2013
Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Merck KGaA, H2 2013
iCo Therapeutics Inc., H2 2013
AEterna Zentaris Inc., H2 2013
MOLOGEN AG, H2 2013
Advinus Therapeutics Pvt. Ltd., H2 2013
Pieris AG, H2 2013
Dafra Pharma International Ltd., H2 2013
aRigen Pharmaceuticals, Inc., H2 2013
Georgia Tech Research Corporation, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Leishmaniasis (Kala-Azar) Therapeutics - Drug Profile Updates
Leishmaniasis (Kala-Azar) Therapeutics - Discontinued Products
Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2013
Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 32

Merck KGaA
iCo Therapeutics Inc.
AEterna Zentaris Inc.
MOLOGEN AG
Advinus Therapeutics Pvt. Ltd.
Pieris AG
Dafra Pharma International Ltd.
aRigen Pharmaceuticals, Inc.
Georgia Tech Research Corporation

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos